Ownership and insider activity for Bio-Techne Corporation (TECH): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Price
| Price | $72.58 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $91.6M | $122.0M | $100.9M | $146.6M | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Short-term Investments | $66.1M | $59.8M | $65.1M | $124.3M | $32.5M | $74.5M | $23.7M | $1.1M | 0 | 0 |
| Receivables | $116.8M | $120.3M | $137.5M | $122.5M | $145.4M | $194.5M | $218.5M | $241.4M | $206.9M | $220.5M |
| Inventory | $60.2M | $85.6M | $91.0M | $103.2M | $116.7M | $141.1M | $171.6M | $179.7M | $189.4M | $195.7M |
| Total Current Assets | $345.3M | $398.4M | $412.6M | $520.9M | $510.6M | $605.6M | $621.5M | $617.4M | $608.3M | $744.4M |
| Property, Plant & Equipment | $135.1M | $145.3M | $154.0M | $248.3M | $281.7M | $288.8M | $324.5M | $342.4M | $319.1M | $299.2M |
| Goodwill | $579.0M | $597.9M | $732.7M | $728.3M | $843.1M | $822.1M | $872.7M | $972.7M | $980.9M | $975.4M |
| Intangible Assets | $452.0M | $446.3M | $579.4M | $516.5M | $616.0M | $531.5M | $534.6M | $507.1M | $365.6M | $303.5M |
| Total Assets | $1.56B | $1.59B | $1.88B | $2.03B | $2.26B | $2.29B | $2.64B | $2.70B | $2.56B | $2.68B |
| Accounts Payable | $16.9M | $18.5M | $16.2M | $23.1M | $29.4M | $33.9M | $25.7M | $38.0M | $25.3M | $26.7M |
| Short-term Debt | 0 | 0 | $12.5M | $12.5M | $12.5M | $12.5M | 0 | 0 | 0 | $14.9M |
| Total Current Liabilities | $135.4M | $78.7M | $102.0M | $106.7M | $152.3M | $176.0M | $128.5M | $159.4M | $175.8M | $163.7M |
| Long-term Debt | $343.8M | $339.0M | $492.7M | $344.2M | $328.8M | $243.4M | $350.0M | $319.0M | $346.0M | $200.0M |
| Total Liabilities | $605.8M | $514.1M | $718.8M | $646.4M | $691.7M | $593.8M | $672.2M | $635.0M | $639.1M | $570.8M |
| Retained Earnings | $799.0M | $876.9M | $931.9M | $1.06B | $1.09B | $1.12B | $1.31B | $1.33B | $1.07B | $1.14B |
| Total Equity | $950.8M | $1.08B | $1.17B | $1.38B | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
| Total Debt | $349.9M | $339.0M | $505.2M | $433.5M | $420.6M | $326.0M | $455.0M | $419.5M | $444.1M | $289.1M |
| Net Debt | $192.2M | $157.2M | $339.1M | $162.6M | $189.0M | $78.9M | $250.7M | $266.7M | $281.9M | $24.4M |
| Working Capital | $209.9M | $319.7M | $310.6M | $414.3M | $358.3M | $429.5M | $493.0M | $458.0M | $432.5M | $580.7M |
Financial Health
| Debt / Equity | 0.14 |
| Current Ratio | 4.55 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 13.20 |
Profitability
| Return on Equity | 8.63% |
| Return on Invested Capital | 7.52% |
| Return on Assets | 6.79% |
| Gross Margin | 65.77% |
| Operating Margin | 20.73% |
| Net Margin | 14.97% |
Related companies: BMRN · CAI · CORT · EXEL · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of TECH: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks